Type 2 diabetes mellitus (T2DM) is associated with comorbid conditions like chronic kidney disease (CKD) and cardiovascular diseases (CVD). They represent a major health issue in a fairly large population of diabetics worldwide. 1,2 These comorbidities contribute heavily to high mortality rates, the burden on healthcare resources and costs, and poor quality of life. Numerous pharmacological and non-pharmacological treatment options have been the mainstay for treating T2DM patients with CKD and CVD.
The burden of CVD and CKD remains substantial even among optimally managed diabetic patients. The latest classes of antidiabetic agents such as SGLT2 (sodium-glucose co-transporter 2) inhibitors, and GLP-1 (glucagon-like peptide-1) receptor agonists have shown significant reductions in cardiovascular and adverse renal outcomes in T2DM patients. References: 1. Einarson TR et al., Cardiovasc…
